Evaluating a new method for seed implantation in abdominal and pelvic cancer
Accuracy of Coplanar Template Assisted Seed Implantation for Abdominal and Pelvic Cancer
This study is testing a new way to place tiny seeds in patients with abdominal and pelvic cancers to see if it makes the treatment safer and more accurate.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 34 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05483452 on ClinicalTrials.gov |
What this trial studies
This study investigates the accuracy and safety of Coplanar Template Assisted Seed Implantation specifically for patients with abdominal and pelvic cancers. Utilizing a digital coplanar template coordinate puncture system, the study aims to enhance the precision of seed implantation procedures, which have previously shown promise in head and neck cancer. By observing patients prospectively, the study seeks to fill the gap in existing research regarding this technique's effectiveness in abdominal and pelvic tumors. The study will include patients who meet specific eligibility criteria and provide informed consent.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 85 with single or multiple abdominal or pelvic tumors who can tolerate puncture procedures.
Not a fit: Patients with poor organ function or those whose tumors are located near critical structures like blood vessels or intestines may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to more accurate and safer treatment options for patients with abdominal and pelvic cancers.
How similar studies have performed: Previous studies have shown the feasibility of coplanar template-assisted techniques in other cancer types, but this specific application for abdominal and pelvic cancers is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ages 18 to 85 2. Single or multiple abdominal or pelvic tumors (solid, partially solid) 3. Without taking drugs affecting coagulation and/or platelet aggregation are used; If used, the drug has been discontinued for a sufficient period of time (e.g. 1 week) 4. KPS\>60 points with expected survival \>3 months, no serious or uncontrolled underlying diseases, clinical evaluation patients can tolerate puncture 5. Planned seed implantation with applicable puncture path 6. With informed consent. Exclusion Criteria: 1. Poor organ function (e.g. Liver decompensation) 2. The lesion close to blood vessels and intestine, or there is portal vein hypertension and superior vena cava compression, etc., which are expected to have high risks of puncture bleeding and intestinal injury 3. Poor compliance, unable to complete coordination 4. Paticipant who is considered inappropriate or unwilling to participate in this clinical trial for other reasons.
Where this trial is running
Beijing, Beijing Municipality
- Peking University Third Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Junjie Wang, M.D. — Peking University Third Hospital
- Study coordinator: Bin Qiu, M.D.
- Email: 542122203@qq.com
- Phone: 01082265968
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.